CFTR and cystic fibrosis: In 2017, the US FDA extended the approval of the Vertex Pharmaceuticals’ cystic fibrosis (CF) drug ivacaftor (CFTR modifier) to a broader range of mutations, based solely on in vitro data (Kingwell, 2017).